ArticleNature communications2018
Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude.
Abstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 179 papers.
0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
179 citing papers in PubMed.
- From barrier to guide: Exploiting disease-specific hemodynamics for enhanced nanodrug targeting in cardiovascular diseases.Pharmaceutical science advances · 2026Review
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Advances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges.Pharmaceutics · 2026Review
- Pharmacokinetics of Ceftriaxone Encapsulated in Carrier Erythrocytes in Experimental Study.Pharmaceutics · 2026Article
- CD5Science advances · 2026Article
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Sequence-regulated, lung-targeting heteropolypeptide nanoparticles via in situ erythrocyte hitchhiking.Nature communications · 2026Article
- Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives.Molecular cancer · 2026Review
- Therapeutic Efficacy of Dual-Targeting Nanoparticles with Low Immunogenicity in the Treatment of Rheumatoid Arthritis.Journal of functional biomaterials · 2026Article
- Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026Review
- When Red Blood Cells Meet Carbon Monoxide: Yin and Yang in Medicines and Pharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles.Materials today. Bio · 2026Article
- In vivo metabolic tagging and targeting of circulating red blood cells.Nature communications · 2026Article
- Blood Cell-Based Drug Delivery Systems: From Biological and Mechanical Design to Clinical Applications.Bioengineering (Basel, Switzerland) · 2026Review
- From Inflammation to Targeted Therapy: Leveraging Neutrophil, Platelet, RBC, and Macrophage Biology for Nanocarrier in Atherosclerosis.Current atherosclerosis reports · 2026Review
- Ionic liquid-coated gold core polymeric nanoparticles for selective neutrophil hitchhiking towards endometriosis treatment.Communications chemistry · 2026Article
- Red blood cell-conjugated biomimetic nanomedicine for enhanced therapy of non-small cell lung cancer.Theranostics · 2026Article
- Nanomedicine for Acute Respiratory Distress Syndrome: From Pathophysiological Mechanisms and Disease Heterogeneity to Precision Therapy.International journal of nanomedicine · 2026Review
119 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Jacob S BrennerPulmonary, Allergy, & Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. brennerj@uphs.upenn.edu.ORCID http://orcid.org/0000-0001-8437-0161
Daniel C PanDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jacob W MyersonDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0002-5686-8437
Oscar A Marcos-ContrerasDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Carlos H VillaDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0002-4632-4751
Priyal PatelPulmonary, Allergy, & Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Hugh HekierskiDepartment of Anesthesiology & Critical Care, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Shampa ChatterjeeInstitute for Environmental Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jian-Qin TaoInstitute for Environmental Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Hamideh ParhizDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Kartik BhamidipatiDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Thomas G UhlerDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Elizabeth D HoodDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Raisa Yu KiselevaDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0001-8065-3551
Vladimir S ShuvaevDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Tea ShuvaevaDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Makan KhoshnejadDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Ian JohnstonDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Jason V GregoryDepartment of Chemical Engineering and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
Joerg LahannDepartment of Chemical Engineering and Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
Tao WangPenn Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0002-4396-7188
Edward CantuDivision of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, 19104, USA.
William M ArmsteadDepartment of Anesthesiology & Critical Care, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Samir MitragotriSchool of Engineering & Applied Sciences, Harvard University, Wyss Institute, Cambridge, MA, 02138, USA.
Vladimir MuzykantovDepartment of Systems Pharmacology and Translational Therapeutics and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. muzykant@mail.med.upenn.edu.
Funding
Training in Molecular Therapeutics for Pediatric CardiologyT32HL007915 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Robert J Levy, JOSEPH W ROSSANO · 1999 to 2026
$13.4MTRAINING GRANT IN HEMOSTASIS AND THROMBOSIST32HL007971 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Rodney M Camire · 2001 to 2026
$10.6MVascular delivery of nanocarriers by erythrocyresR01HL143806 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2018 to 2021
$2.8MTRANSFUSION MEDICINE RESEARCH TRAINING PROGRAMT32HL007775 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI SIEGEL, DONALD LAWRENCE · 1993 to 2023
$2.8MBridging multiple scales in modeling targeted drug nanocarrier deliveryU01EB016027 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI ECKMANN, DAVID M, RADHAKRISHNAN, RAVI · 2013 to 2017
$2.7MDrug delivery by carrier erythrocytesR01HL121134 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2014 to 2017
$2.6MTargeted nanomedicine for ALI and I/RR01HL125462 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2015 to 2018
$2.3MDelivery of Anti-thrombotic Drugs by Blood CellsR01HL090697 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2008 to 2012
$2.0MTargeting Carriers with Controlled Geometry to EndotheliumR01HL087036 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2008 to 2012
$2.0MNanonscale drug carriers for the treatment of acute respiratory distress syndromeK08HL138269 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB · 2017 to 2021
$746kTargeted Drug Delivery For Acute Respiratory Distress SyndromeF32HL129665 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB · 2015 to 2016
$115kNHLBI NIH HHS F32 HL129665NHLBI NIH HHS K08 HL138269NHLBI NIH HHS R01 HL087036NHLBI NIH HHS R01 HL090697NHLBI NIH HHS R01 HL121134NHLBI NIH HHS R01 HL125462NHLBI NIH HHS R01 HL143806NHLBI NIH HHS T32 HL007775NHLBI NIH HHS T32 HL007915NHLBI NIH HHS T32 HL007971NIBIB NIH HHS U01 EB016027NIH HHS HL087036NIH HHS HL090697NIH HHS HL121134
Abstract
Drug delivery by nanocarriers (NCs) has long been stymied by dominant liver uptake and limited target organ deposition, even when NCs are targeted using affinity moieties. Here we report a universal solution: red blood cell (RBC)-hitchhiking (RH), in which NCs adsorbed onto the RBCs transfer from RBCs to the first organ downstream of the intravascular injection. RH improves delivery for a wide range of NCs and even viral vectors. For example, RH injected intravenously increases liposome uptake in the first downstream organ, lungs, by ~40-fold compared with free NCs. Intra-carotid artery injection of RH NCs delivers >10% of the injected NC dose to the brain, ~10× higher than that achieved with affinity moieties. Further, RH works in mice, pigs, and ex vivo human lungs without causing RBC or end-organ toxicities. Thus, RH is a clinically translatable platform technology poised to augment drug delivery in acute lung disease, stroke, and several other diseases.
Indexed as
AdsorptionAnimalsDrug CarriersDrug Delivery SystemsErythrocytesHumansLungLung DiseasesMice, Inbred C57BLNanoparticlesRatsSwineDrug Carriers
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.